Adding Erlotinib to Chemoradiation Improves Overall Survival but not Progression-Free Survival in Stage III Non-Small-Cell Lung Cancer

Adding Erlotinib to Chemoradiation Improves Overall Survival but not Progression-Free Survival in Stage III Non-Small-Cell Lung Cancer

Bibliographic Details
Main Authors: Komaki, Ritsuko, Allen, Pamela K., Wei, Xiong, Blumenschein, George R., Tang, Ximing, Lee, J. Jack, Welsh, James W., Wistuba, Ignacio I., Liu, Diane D., Hong, Waun Ki
Format: Online
Language:English
Published: 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432249/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432249/

Similar Items